Longeveron LLC Cash Flow Conversion Efficiency
Longeveron LLC cash flow conversion efficiency. Based on the latest financial reports, Longeveron LLC (LGVN) has a cash flow conversion efficiency ratio of -0.384x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.65 Million) by net assets ($14.71 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Longeveron LLC (2018–2025)
Cash flow conversion efficiency of Longeveron LLC from 2018 to 2025. This chart illustrates how Longeveron LLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Longeveron LLC stock quote for real-time trading data and today's change.
Longeveron LLC Cash Flow Conversion Ratio Explained
Longeveron LLC cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Longeveron LLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Longeveron LLC ranked by their cash flow conversion efficiency. Also see LGVN market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BIONXT SOLUTIONS INC.
F:BXT
|
0.080x |
|
Radiant Innovation
TWO:3373
|
0.014x |
|
Acarix A/S
ST:ACARIX
|
-0.270x |
|
Culico Metals Inc.
V:CLCO
|
-0.044x |
|
CHINA NEW ENERGY LS-00025
F:9H5
|
N/A |
|
Eqva ASA
OL:EQVA
|
0.112x |
|
Sikko Industries Limited
NSE:SIKKO
|
-0.100x |
|
Rubean AG
F:R1B
|
N/A |
Annual Cash Flow Conversion Efficiency for Longeveron LLC (2018–2025)
The table below shows the annual cash flow conversion efficiency of Longeveron LLC from 2018 to 2025. Review LGVN free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.67 Million | $-18.64 Million | -3.285x | -418.52% |
| 2024-12-31 | $21.89 Million | $-13.87 Million | -0.634x | +77.52% |
| 2023-12-31 | $6.74 Million | $-19.00 Million | -2.819x | -313.74% |
| 2022-12-31 | $20.50 Million | $-13.97 Million | -0.681x | -164.81% |
| 2021-12-31 | $37.45 Million | $-9.64 Million | -0.257x | +78.70% |
| 2020-12-31 | $1.96 Million | $-2.36 Million | -1.208x | -124.58% |
| 2019-12-31 | $4.45 Million | $-2.39 Million | -0.538x | +29.22% |
| 2018-12-31 | $6.81 Million | $-5.18 Million | -0.760x | -- |
About Longeveron LLC
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; com… Read more